| Active substance |
Capecitabine |
| Also known as |
Xeloda |
| Blood pressure |
No significant effect on blood pressure |
| Chemical name |
5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine |
| Dosage (medical) |
Typically, 1250 mg/mВІ twice daily for 2 weeks followed by a 1-week rest period, administered as 3-week cycles |
| Dosage (sports) |
Not applicable |
| Effects |
Effective in halting the progression of certain types of cancers by interfering with DNA production |
| Formula |
C15H22FN3O6 |
| Half-life |
Approximately 38-45 minutes |
| Hepatotoxicity |
Possible, especially in patients with pre-existing liver conditions |
| Lab Test |
Monitoring of complete blood counts, liver and renal function tests recommended |
| Main action |
Antineoplastic agent |
| Side effects |
Diarrhea, hand-foot syndrome, nausea, vomiting, fatigue, dermatitis, neutropenia, anemia |
| Storage conditions |
Store at room temperature, protect from moisture and light |
| Substance class |
Antimetabolite, Fluoropyrimidine |
| Trade name |
Xeloda |
| Use in sports |
None |
| WAREHOUSE |
International Warehouse 2 |
| Water Retention |
No significant effect |
| Manufacturer |
Med Ilac |
